WRBY | Ticker Profile - Titan Protect

WRBY

Warby Parker Inc.

Healthcare · Medical Instruments & Supplies · NYQ

$22.72

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.2B

Total market value of the company

Trailing P/E

2,568.00

Expensive — high growth expected

Forward P/E

38.12

Based on estimated future earnings — lower means cheaper

Rev Growth

+8.3%

Year-over-year revenue change

Profit Margin

0.2%

How much profit the company keeps from each dollar of revenue

ROE

0.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$31.50

+39% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 12 analysts covering this stock

About Warby Parker Inc.

Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

https://www.warbyparker.com

Country: United States Employees: 2,275 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.646

Good returns relative to risk taken

Kelly Fraction

0.0446

Modest edge detected — smaller position warranted

Calmar Ratio

0.473

Drawdown risk outweighs the returns — higher risk profile

Annual Return

24.0%

Historical annualised return based on price data

Max Drawdown

-50.7%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.96

Significantly more volatile than the market

52W High

$31.00

27% below the year high

52W Low

$14.96

52% above the year low

Avg Volume

2,819,837

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.01

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

63.23

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.33

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.89

Like current ratio but excludes inventory — stricter test

Gross Margin

53.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

1.0%

Profit from core operations before interest and tax

Free Cash Flow

$32M

Positive — the business generates more cash than it spends

Revenue (TTM)

$891M

Total revenue over the last 12 months

Net Income

$1M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$35.00

Target Median

$31.50

Target Low

$24.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go